Lipoprotein(a): The Cardiovascular Risk Factor Guidelines Now Say to Measure Once

The shift is captured in a 2025 clinical rationale paper in the European Journal of Preventive Cardiology, which lays out the case that Lp(a) meets the established criteria used to judge whether any new test belongs in routine population screening. The authors argue that measuring Lp(a) once is no longer a niche specialist's tool but a piece of preventive medicine that should sit alongside the standard lipid panel — a position now endorsed by the European and Canadian lipid guidelines and by the National Lipid Association.

What changed is not the particle itself — Lp(a) was first described in the 1960s — but the strength of the evidence linking it causally to disease. Large genetic studies using a method called Mendelian randomization, which exploits the random inheritance of gene variants to mimic a randomized trial, have shown that people who inherit gene variants producing higher Lp(a) levels go on to develop more atherosclerotic cardiovascular disease and more calcific aortic stenosis. That signal holds across ethnicities, which matters because Lp(a) distributions differ substantially between populations.

Lp(a) looks superficially like LDL — the familiar "bad cholesterol" — but with an extra protein, apolipoprotein(a), wrapped around it. That structural quirk appears to make it more atherogenic per particle than LDL, and it also seems to promote inflammation and possibly clotting in vessel walls. Crucially, your Lp(a) level is roughly 80–90% determined by the gene you inherited. It barely budges with diet, exercise, or the statins that lower LDL. For most people, the number you have at 25 is, give or take, the number you'll have at 65 — which is exactly why a single lifetime measurement is enough.

The rationale paper frames the clinical stakes bluntly: in people with markedly elevated Lp(a), the lifetime cardiovascular risk is comparable to that of untreated familial hypercholesterolemia — a well-known inherited cholesterol disorder that cardiology has taken seriously for decades. The difference is that familial hypercholesterolemia gets flagged because LDL is on every lab panel. Lp(a), historically, has not been.

If Lp(a) can't be lowered by today's standard tools, why measure it? The honest answer is that knowing the number changes the aggressiveness with which the modifiable risks are managed. A person with high Lp(a) and a borderline LDL is not in the same risk category as a person with the same LDL and a low Lp(a). Guidelines increasingly treat elevated Lp(a) as a thumb on the scale — a reason to push harder on LDL targets, blood pressure, smoking cessation, and to look more carefully at family members who may share the inherited risk.

The rationale paper argues that integrating Lp(a) into global cardiovascular risk assessment is likely to generate health-system savings by enabling earlier, more targeted prevention, while reinforcing a direction that a growing number of clinical guidelines and consensus statements are already moving in. That's a moderate-strength claim worth taking seriously, but it is a projection built on screening-criteria logic and modeling, not yet on a completed population-screening trial.

Two honest caveats belong in any sober account of Lp(a). First, the causal genetic evidence is strong, but the precise risk increase tied to any individual's specific level — and how to weigh it against other risk factors in a given patient — is still an area of active refinement. Second, drugs designed to lower Lp(a) directly, including several RNA-based therapies, are in advanced clinical trials but have not yet been shown in completed outcome trials to reduce cardiovascular events. That is the missing piece that would move Lp(a) from "risk marker worth knowing" to "risk factor we can directly treat."

Until those trial readouts arrive, the practical value of screening sits in stratification and family awareness rather than in a specific Lp(a)-lowering prescription. That is a meaningful but bounded benefit, and it is the one the current guidelines are endorsing.

Lp(a) is not a new discovery, and the guideline shift is not a revolution. It is, more accurately, a long-overdue alignment between what genetic epidemiology has been saying for years and what clinicians are now being asked to do in practice. A single blood test, taken once, surfaces a piece of inherited cardiovascular risk that has been sitting invisibly on millions of charts. The treatment landscape will keep evolving; the case for knowing the number, the rationale paper argues, no longer depends on waiting for it.